Amniotic membrane grafts, “fresh” or frozen? A clinical and in vitro comparison

Philip J Adds, Charles J Hunt, John K G Dart

Abstract

Background/aims—The use of “fresh” (hypothermically stored) and frozen amniotic membrane (AM) was compared in a patient with cicatricial pemphigoid with stem cell failure. The viability of both “fresh” and frozen AM epithelial cells was assessed after storage.

Methods—AM was stored at either +4°C ("fresh") or at −80°C (frozen). A “fresh” graft was applied to the cornea following superficial keratectomy. Subsequently, a further frozen graft was applied to the same eye. Viability of the stored AM epithelium was assessed by investigating membrane integrity and mitochondrial activity.

Results—In both cases the cornea re-epithelialised and visual acuity improved. Improvement, however, was not sustained.

Conclusion—Although both procedures led to an improvement in visual acuity, “fresh” tissue performed no better than frozen in promoting re-epithelialisation. The authors suggest that logistical, safety, and cost considerations outweigh any benefits of using “fresh” as opposed to frozen graft material.

Amniotic membrane has been used sporadically for many years in a variety of clinical applications. Recently, there has been a resurgence of interest in amniotic membrane transplantation for ocular surface reconstruction. Various methods have been used to preserve amniotic membrane including “fresh” (or more appropriately hypothermic) storage, freezing, and freeze drying. Maintenance of the integrity of the basement membrane and stromal matrix appears to be central to promoting rapid re-epithelialisation, and storage conditions were chosen to optimise this.

We report the use of amniotic membrane grafts, both hypothermically stored (in CPTES + chondroitin sulphate) and glycerolised frozen, in a case of severe pseudopemphigoid secondary to glaucoma therapy. In the absence of banked frozen amnion and because of the pressing nature of the patient’s condition, it was decided to proceed initially using hypothermically stored tissue. A subsequent regraft utilised banked frozen amnion.

A low grade inflammatory response has been reported under conditions where viable amniotic epithelial cells are present. The viability of the amniotic membrane graft epithelial cells was therefore assessed for both hypothermically stored and frozen tissue after storage. This was done by investigating mitochondrial activity and cell membrane integrity.

Patient and methods

CLINICAL CONDITION

The patient was a 50 year old man with drug induced cicatricial pemphigoid with stem cell failure. Total corneal epithelial (stem cell) failure was confirmed by impression cytology which showed the presence of goblet cells and cytokeratin 19 (conjunctival epithelial phenotype) staining epithelial cells with an absence of any cytokeratin 3 staining (corneal epithelial phenotype) epithelium.

His disease followed 6 years of treatment with guanethidine and adrenaline eye drops for open angle glaucoma. The left eye was completely blind secondary to glucoma, and the right eye had become blind due to a superficial corneal vascular membrane. The underlying corneal stroma was normal. Following superficial keratectomy and amnion grafting, the patient’s vision improved, but then deteriorated again because of a recurrence of a thick neovascular pannus. The procedure was repeated, with a 360° stem cell allograft.

DONOR SELECTION

Processing and testing of the tissue and microbiological screening of the donor required a 10 day lead time before elective surgery for the first, hypothermically stored “fresh” graft. For this reason, timing of the surgery and retrieval of the donated placenta were of crucial importance. A donor, due to undergo elective caesarean section 2 weeks before the proposed date of the eye surgery, was selected. A detailed medical and behavioural history together with signed consent was obtained from the donor. Serological tests were carried out by both enzyme linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). Exclusion criteria were consistent with those developed by the NBS for blood, tissue and cord
blood donation. The same procedure was followed for the donor of the frozen tissue. Frozen tissue is banked for up to 12 months, and can be used after the initial 6 month quarantine period, which allows for mandatory post-donation retesting.

PROCESSING
The placenta was retrieved intact and processed under sterile conditions. The chorioamnion was stripped from the placenta and, following antibiotic decontamination, the amniotic membrane was separated from the chorion, cut into 2 cm squares and mounted on nitrocellulose backing paper. The grafts were then stored individually in sterile CPTES solution containing 2.5% chondroitin sulphate (CS) at +4°C. Amniotic membrane for the second graft was processed in a similar manner but stored frozen in a 50% glycerol-Hanks’s balanced salts solution at −80°C. Samples of both membranes were taken before and after processing for bacteriology and viability assays. The grafts were quarantined until results of the serological and bacteriological tests, the epithelial assessment, and the donor’s medical history had been reviewed.

ASSESSMENT OF GRAFT EPITHELIUM
The viability of the AM epithelium was assessed by two methods: a fluorescent membrane integrity assay employing acridine orange/propidium iodide (AO/PI) and a tetrazolium reductase assay of mitochondrial activity. Mitochondrial activity was assessed on AM from three placentas including those used clinically. Microscopic evaluation using AO/PI was carried out after storage both at +4°C and −80°C.

Results and discussion
In both cases, all serological and bacteriology results were negative. The hypothermically stored tissue was released for use within 12 days, while the frozen tissue was released after 6 months.

The assessment of the graft epithelium is shown in Figures 1 and 2. There were similar levels of mitochondrial activity in both hypothermically stored and frozen tissue, compared with heat treated non-viable controls. The results of the AO/PI membrane integrity tests confirmed that the graft epithelia, stored by both methods, were non-viable.

Following superficial keratectomy, the “fresh” AM graft was transplanted onto the patient’s right eye 14 days after retrieval of the placenta. Postoperative results were initially encouraging. Six weeks following the operation, the cornea had almost completely re-epithelialised, giving a functional improvement in vision to 3/60. However, although the epithelium was initially relatively clear, after 6 months the thick, neovascular, conjunctival derived membrane had recurred with a concomitant reduction in vision.

The procedure was repeated after 7 months using a frozen AM graft with a stem cell allograft. This epithelialised much faster and was healed in 3 weeks, with an improvement in vision to 4/60. Again, the improvement was not maintained, and the patient has since had a stem cell allograft from a living related donor, resulting in a clear corneal epithelial phenotype at the present time (2 months after surgery).

Amniotic membrane grafting, though becoming more widespread, is a low volume tissue product from the point of view of the tissue banks. Current practice dictates a short shelf life for frozen amnion, which inevitably leads to outdating and discard of some tissue. An alternative to this might be an “on-demand” service whereby amnion is procured and stored under hypothermic conditions for named patients as and when required.

There are however a number of clinical and practical difficulties in using hypothermically
Amniotic membrane grafts, “fresh” or frozen?

preserved membrane grafts compared with frozen material. The first, and most important of these, is a theoretical risk of disease transmission. Because of the short time between procurement and implantation, a serological retest of the donor is not possible. Though this risk was reduced both by careful donor screening and additional PCR testing for HIV-I and II and hepatitis C virus (HCV), a slight risk inevitably remains. Frozen storage of the tissue permits repeat blood testing of the donor 6 months following donation of the tissue, and effectively eliminates this risk.

The second difficulty was logistical: the need to find a suitable donor sufficiently far in advance of surgery to allow processing and testing, and coordination with the admission to hospital of the recipient. This does not arise with banked, frozen tissue.

The third drawback in using this method is that the grafts have to be prepared to order for a particular patient, the rest of the amniotic membrane being discarded. If the grafts are prepared for frozen storage, up to 30 can be prepared from one placenta giving much greater cost effectiveness.

The laboratory tests show that the graft epithelium was non-viable in both cases. The clinical results from this patient showed no obvious benefit in using “fresh” AM compared with the frozen material.

Though it is possible to produce hypothermically stored amniotic membrane grafts that appear to be comparable to frozen grafts both morphologically and clinically, it is our opinion that on safety, logistical, and cost grounds the disadvantages are likely to outweigh any benefits. The North London Tissue Bank has since instituted a rolling programme of frozen amnion banking which accepts the likely outdating of some grafts, but ensures a continuity of supply for the clinician.


www.bjophthalmol.com